688221 前沿生物-U
盘后交易 09-16 15:00:01
资讯
新帖
简况
每周股票复盘:前沿生物(688221)营收同比增434.27%
证券之星 · 09-06
每周股票复盘:前沿生物(688221)营收同比增434.27%
前沿生物(688221)2026年中报简析:营收净利润同比双双增长,盈利能力上升
证券之星 · 09-01
前沿生物(688221)2026年中报简析:营收净利润同比双双增长,盈利能力上升
前沿生物(688221)披露2026年半年度报告,8月31日股价下跌6.37%
证券之星 · 08-31
前沿生物(688221)披露2026年半年度报告,8月31日股价下跌6.37%
前沿生物(688221.SH)发布半年度业绩,归母净利润1.49亿元,同比扭亏为盈
智通财经 · 08-30
前沿生物(688221.SH)发布半年度业绩,归母净利润1.49亿元,同比扭亏为盈
前沿生物(688221)6月30日股东户数2万户,较上期增加23.58%
证券之星 · 08-30
前沿生物(688221)6月30日股东户数2万户,较上期增加23.58%
每周股票复盘:前沿生物(688221)洛索洛芬钠贴剂获批
证券之星 · 08-23
每周股票复盘:前沿生物(688221)洛索洛芬钠贴剂获批
前沿生物(688221)披露FB3002洛索洛芬钠贴剂获得药品注册证书的公告,8月21日股价下跌9.38%
证券之星 · 08-21
前沿生物(688221)披露FB3002洛索洛芬钠贴剂获得药品注册证书的公告,8月21日股价下跌9.38%
每周股票复盘:前沿生物(688221)股东减持致持股比降至4.9999%
证券之星 · 08-16
每周股票复盘:前沿生物(688221)股东减持致持股比降至4.9999%
前沿生物(688221)披露持股5%以上股东权益变动触及1%及5%刻度的提示性公告,8月12日股价下跌0.14%
证券之星 · 08-12
前沿生物(688221)披露持股5%以上股东权益变动触及1%及5%刻度的提示性公告,8月12日股价下跌0.14%
每周股票复盘:前沿生物(688221)现875万元大宗交易
证券之星 · 08-09
每周股票复盘:前沿生物(688221)现875万元大宗交易
每周股票复盘:前沿生物(688221)现8笔折价13.74%大宗交易
证券之星 · 07-12
每周股票复盘:前沿生物(688221)现8笔折价13.74%大宗交易
前沿生物-U股东拟减持股份,计划出售最多2.6%股权
投资观察 · 07-10
前沿生物-U股东拟减持股份,计划出售最多2.6%股权
前沿生物-U股东拟减持,8月3日至11月2日期间合计减持比例最高可达2.6%
美股速递 · 07-10
前沿生物-U股东拟减持,8月3日至11月2日期间合计减持比例最高可达2.6%
每周股票复盘:前沿生物(688221)股价异动登龙虎榜
证券之星 · 07-05
每周股票复盘:前沿生物(688221)股价异动登龙虎榜
股市必读:前沿生物(688221)登7月2日交易所龙虎榜
证券之星 · 07-03
股市必读:前沿生物(688221)登7月2日交易所龙虎榜
前沿生物:股票交易异常波动公司经营正常无未披露重大事项
证券之星 · 07-02
前沿生物:股票交易异常波动公司经营正常无未披露重大事项
每周股票复盘:前沿生物(688221)2025年年度股东会多项议案获通过
证券之星 · 05-24
每周股票复盘:前沿生物(688221)2025年年度股东会多项议案获通过
每周股票复盘:前沿生物(688221)2025年亏损26,805.30万元
证券之星 · 05-17
每周股票复盘:前沿生物(688221)2025年亏损26,805.30万元
前沿生物(688221)披露2025年年度股东会会议资料,5月14日股价下跌3.96%
证券之星 · 05-14
前沿生物(688221)披露2025年年度股东会会议资料,5月14日股价下跌3.96%
5月11日前沿生物涨8.40%,易方达医疗保健行业混合A基金重仓该股
证券之星 · 05-11
5月11日前沿生物涨8.40%,易方达医疗保健行业混合A基金重仓该股
加载更多
公司概况
公司名称:
前沿生物药业(南京)股份有限公司
所属行业:
医药制造业
上市日期:
2020-10-28
主营业务:
前沿生物药业(南京)股份有限公司的主营业务是抗病毒和肌肉骨骼疼痛治疗药物的研发、生产和销售。公司的主要产品是艾可宁。公司斩获多项政府及行业荣誉,获评国家专精特新小巨人企业、江苏省企业技术中心、江苏瞪羚企业、中国制药工业TOP101;同时入选南京生物医药产业创新投资促进会第一届会员成就榜,取得海外BD开拓成就榜、社会责任与公益贡献成就榜、协会发展特别贡献榜多项荣誉。
发行价格:
20.50
{"stockData":{"symbol":"688221","market":"SH","secType":"STK","nameCN":"前沿生物-U","latestPrice":15.65,"timestamp":1789542001000,"preClose":15.54,"halted":0,"volume":7263985,"delay":0,"changeRate":0.0071,"floatShares":375000000,"shares":375000000,"eps":-0.0582,"marketStatus":"盘后交易","change":0.11,"latestTime":"09-16 15:00:01","open":15.54,"high":15.82,"low":15.32,"amount":113000000,"amplitude":0.0322,"askPrice":15.66,"askSize":36,"bidPrice":15.65,"bidSize":83,"shortable":0,"etf":0,"ttmEps":-0.0582,"tradingStatus":3,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789608600000},"marketStatusCode":4,"adr":0,"adjPreClose":15.54,"symbolType":"stock_kcb","openAndCloseTimeList":[[1789522200000,1789529400000],[1789534800000,1789542000000]],"highLimit":17.09,"lowLimit":13.99,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":374578653,"isCdr":false,"pbRate":5.63,"roa":"--","roe":"15.59%","epsLYR":-0.72,"committee":-0.168971,"marketValue":5862000000,"turnoverRate":0.0194,"status":0,"afterMarket":{"amount":0,"volume":0,"close":15.65,"buyVolume":2000,"sellVolume":0,"time":1789542468746,"indexStatus":"盘后交易 09-16 15:07:48","preClose":15.54},"floatMarketCap":5862000000},"requestUrl":"/m/hq/s/688221","defaultTab":"news","newsList":[{"id":"2665365635","title":"每周股票复盘:前沿生物(688221)营收同比增434.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665365635","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665365635?lang=zh_cn&edition=full","pubTime":"2026-09-06 01:35","pubTimestamp":1788629712,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘,前沿生物报收于17.42元,较上周的18.84元下跌7.54%。本周关注点来自业绩披露要点:2026年上半年公司实现营业收入313,296,180.72元,同比上升434.27%。2026年上半年,公司实现营收31,330万元,同比增长434.27%;归母净利润14,892.96万元。FB3002获药品注册证书,小核酸项目与GSK达成合作。截至2026年9月4日,上述资金已全部归还至募集资金账户,并通知保荐机构及保荐代表人。研发投入占营业收入的比例为20.65%,较上年同期下降61.10个百分点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664262885","title":"前沿生物(688221)2026年中报简析:营收净利润同比双双增长,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2664262885","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664262885?lang=zh_cn&edition=full","pubTime":"2026-09-01 06:10","pubTimestamp":1788214213,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期前沿生物发布2026年中报。截至本报告期末,公司营业总收入3.13亿元,同比上升434.27%,归母净利润1.49亿元,同比上升252.98%。本报告期前沿生物盈利能力上升,毛利率同比增幅171.24%,净利率同比增幅128.63%。本文数据来源于前沿生物2026年中报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100004825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663071302","title":"前沿生物(688221)披露2026年半年度报告,8月31日股价下跌6.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663071302","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663071302?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:53","pubTimestamp":1788170018,"startTime":"0","endTime":"0","summary":"前沿生物药业(南京)股份有限公司于近日披露《2026年半年度报告》。2026年上半年,公司实现营业收入313,296,180.72元,同比上升434.27%;利润总额为148,929,627.03元,上年同期为-97,352,610.68元;归属于上市公司股东的净利润为148,929,627.03元,上年同期为-97,352,610.68元;扣除非经常性损益后的净利润为128,300,532.76元,上年同期为-114,735,072.42元。研发投入占营业收入的比例为20.65%,较上年同期下降61.10个百分点。2026年2月,公司与GSK达成两款小核酸管线产品的全球独家授权合作,本报告期确认相关营业收入27,655.78万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100025411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663041123","title":"前沿生物(688221.SH)发布半年度业绩,归母净利润1.49亿元,同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2663041123","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663041123?lang=zh_cn&edition=full","pubTime":"2026-08-30 18:47","pubTimestamp":1788086822,"startTime":"0","endTime":"0","summary":"智通财经APP讯,前沿生物(688221.SH)发布2026年半年度报告,报告期内,公司实现营业收入3.13亿元,同比增加434.27%;归属于上市公司股东的净利润1.49亿元,同比扭亏为盈;归属于上市公司股东的扣除非经常性损益的净利润1.28亿元,同比扭亏为盈;基本每股收益0.4元。报告期公司营业收入同比增加434.27%,主要系本期新增授权许可收入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"前沿生物(688221.SH)发布半年度业绩,归母净利润1.49亿元,同比扭亏为盈","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663049465","title":"前沿生物(688221)6月30日股东户数2万户,较上期增加23.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663049465","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663049465?lang=zh_cn&edition=full","pubTime":"2026-08-30 17:07","pubTimestamp":1788080871,"startTime":"0","endTime":"0","summary":"证券之星消息,近日前沿生物披露,截至2026年6月30日公司股东户数为2.0万户,较3月31日增加3824.0户,增幅为23.58%。户均持股数量由上期的2.31万股减少至1.87万股,户均持股市值为41.86万元。在化学制药行业个股中,前沿生物股东户数低于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.67万户。从股价来看,2026年3月31日至2026年6月30日,前沿生物区间涨幅为18.21%,在此期间股东户数增加3824.0户,增幅为23.58%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000011123.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661421146","title":"每周股票复盘:前沿生物(688221)洛索洛芬钠贴剂获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2661421146","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661421146?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:16","pubTimestamp":1787422572,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘,前沿生物报收于20.0元,较上周的21.97元下跌8.97%。本周关注点公司公告汇总:前沿生物洛索洛芬钠贴剂获药品注册证书公司公告汇总前沿生物药业(南京)股份有限公司下属全资子公司齐河前沿生物药业有限公司近日收到国家药品监督管理局颁发的洛索洛芬钠贴剂《药品注册证书》,批准该药品生产。洛索洛芬钠贴剂用于骨关节炎、肌肉痛、外伤导致的肿胀或疼痛的消炎和镇痛,为热熔胶类贴剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661269912","title":"前沿生物(688221)披露FB3002洛索洛芬钠贴剂获得药品注册证书的公告,8月21日股价下跌9.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661269912","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661269912?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:37","pubTimestamp":1787305022,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘,前沿生物报收于20.0元,较前一交易日下跌9.38%,最新总市值为74.92亿元。该股当日开盘21.45元,最高21.49元,最低19.8元,成交额达5.14亿元,换手率为6.77%。前沿生物药业(南京)股份有限公司下属全资子公司齐河前沿生物药业有限公司近日收到国家药品监督管理局颁发的洛索洛芬钠贴剂《药品注册证书》,批准该药品生产。洛索洛芬钠贴剂用于骨关节炎、肌肉痛、外伤导致的肿胀或疼痛的消炎和镇痛,为热熔胶类贴剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100032060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659175640","title":"每周股票复盘:前沿生物(688221)股东减持致持股比降至4.9999%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659175640","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659175640?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:27","pubTimestamp":1786814830,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘,前沿生物报收于21.97元,较上周的21.22元上涨3.53%。本周,前沿生物8月14日盘中最高价报22.92元。股本股东变化股东CHANGJIN WANG(王昌进)因减持及总股本变动,持股比例由5.6222%下降至4.9999%,不再为持股5%以上股东。公司公告汇总前沿生物公告,持股5%以上股东CHANGJIN WANG通过集中竞价和大宗交易合计减持2,330,767股,持股比例由5.8538%降至4.9999%。本次变动未导致公司控制权变更,所持股份无质押或冻结情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903496","title":"前沿生物(688221)披露持股5%以上股东权益变动触及1%及5%刻度的提示性公告,8月12日股价下跌0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903496","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658903496?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:10","pubTimestamp":1786543830,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘,前沿生物报收于21.46元,较前一交易日下跌0.14%,最新总市值为80.38亿元。近日,前沿生物药业(南京)股份有限公司发布《关于持股5%以上股东权益变动触及1%及5%刻度的提示性公告》。公告显示,公司持股5%以上股东CHANGJIN WANG(王昌进)因减持股份及公司总股本变动,持股比例由5.6222%下降至4.9999%,触及权益变动1%和5%的整数倍刻度线。信息披露义务人已披露《简式权益变动报告书》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200040039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658732496","title":"每周股票复盘:前沿生物(688221)现875万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2658732496","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658732496?lang=zh_cn&edition=full","pubTime":"2026-08-09 01:57","pubTimestamp":1786211832,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘,前沿生物(688221)报收于21.22元,较上周的17.7元上涨19.89%。本周,前沿生物8月7日盘中最高价报21.29元。8月3日盘中最低价报16.94元。前沿生物当前最新总市值79.49亿元,在化学制药板块市值排名66/149,在两市A股市值排名2198/5205。本周关注点来自交易信息汇总:前沿生物现875万元大宗交易交易信息汇总8月6日前沿生物现875万元大宗交易以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650151046","title":"每周股票复盘:前沿生物(688221)现8笔折价13.74%大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2650151046","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650151046?lang=zh_cn&edition=full","pubTime":"2026-07-12 01:47","pubTimestamp":1783792030,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘,前沿生物报收于27.3元,较上周的27.73元下跌1.55%。公司公告汇总:董事陆荣健、王昌进拟各自减持不超过480万股,减持比例均不超1.2814%。交易信息汇总7月10日前沿生物出现8笔折价13.74%的大宗交易,合计成交金额1601.44万元。7月9日发生12笔大宗交易,机构净买入2013.54万元。7月7日发生2笔大宗交易,成交金额601.94万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176050754","title":"前沿生物-U股东拟减持股份,计划出售最多2.6%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1176050754","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176050754?lang=zh_cn&edition=full","pubTime":"2026-07-10 20:07","pubTimestamp":1783685232,"startTime":"0","endTime":"0","summary":"前沿生物-U(688221.SS)发布公告称,公司部分股东计划减持股份。根据安排,相关股东拟在2026年8月3日至11月2日期间,通过集中竞价或大宗交易方式,合计减持公司股份不超过总股本的2.6%。此次减持计划若实施完毕,将可能对公司的股权结构产生一定影响。市场分析人士指出,股东减持通常基于自身资金需求或投资安排,投资者需关注减持的具体进展及其对公司股价的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688221","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102207479","title":"前沿生物-U股东拟减持,8月3日至11月2日期间合计减持比例最高可达2.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102207479","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102207479?lang=zh_cn&edition=full","pubTime":"2026-07-10 19:51","pubTimestamp":1783684273,"startTime":"0","endTime":"0","summary":"前沿生物-U发布公告称,公司部分股东计划在2024年8月3日至11月2日期间,通过集中竞价或大宗交易方式,合计减持公司股份不超过2.6%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649367694","title":"每周股票复盘:前沿生物(688221)股价异动登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2649367694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649367694?lang=zh_cn&edition=full","pubTime":"2026-07-05 01:50","pubTimestamp":1783187422,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,前沿生物报收于27.73元,较上周的19.62元上涨41.34%。本周,前沿生物7月2日盘中最高价报28.45元。交易信息汇总沪深交易所2026年7月2日公布的交易公开信息显示,前沿生物因有价格涨跌幅限制的连续3个交易日内收盘价格涨幅偏离值累计达到30%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。董事会确认无应披露未披露事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648568258","title":"股市必读:前沿生物(688221)登7月2日交易所龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2648568258","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648568258?lang=zh_cn&edition=full","pubTime":"2026-07-03 01:31","pubTimestamp":1783013468,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘,前沿生物报收于27.33元,上涨2.78%,换手率10.61%,成交量39.75万手,成交额10.84亿元。龙虎榜上榜前沿生物因有价格涨跌幅限制的连续3个交易日内收盘价格涨幅偏离值累计达到30%,于2026年7月2日登上沪深交易所龙虎榜;此次为近5个交易日内第1次上榜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300001574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648509216","title":"前沿生物:股票交易异常波动公司经营正常无未披露重大事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2648509216","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648509216?lang=zh_cn&edition=full","pubTime":"2026-07-02 18:20","pubTimestamp":1782987607,"startTime":"0","endTime":"0","summary":"前沿生物(688221.SH)公告称,公司股票连续三个交易日内(2026年7月2日、7月1日、6月30日)收盘价格涨幅偏离值累计达到30%,属于股票交易异常波动情形。经公司自查及向实际控制人问询,公司日常经营情况正常,未发生重大变化,不存在应披露而未披露的重大信息,包括并购重组、股份发行等事项。公司提醒投资者注意股价波动风险,理性决策。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200032785.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637684373","title":"每周股票复盘:前沿生物(688221)2025年年度股东会多项议案获通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2637684373","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637684373?lang=zh_cn&edition=full","pubTime":"2026-05-24 02:16","pubTimestamp":1779560174,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总:前沿生物2025年年度股东会审议通过2025年年度报告及利润分配方案等多项议案。公司公告汇总:北京国枫(南京)律师事务所确认前沿生物2025年年度股东会表决程序及结果合法有效。所有议案均获通过,无否决议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636061166","title":"每周股票复盘:前沿生物(688221)2025年亏损26,805.30万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636061166","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636061166?lang=zh_cn&edition=full","pubTime":"2026-05-17 02:13","pubTimestamp":1778955190,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘,前沿生物报收于22.82元,较上周的22.51元上涨1.38%。本周,前沿生物5月12日盘中最高价报25.51元。5月11日盘中最低价报22.28元。前沿生物当前最新总市值85.48亿元,在化学制药板块市值排名68/150,在两市A股市值排名2371/5203。公司2025年度亏损26,805.30万元,不进行利润分配。董事会共召开8次会议,持续推进公司治理体系建设。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700000538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635745685","title":"前沿生物(688221)披露2025年年度股东会会议资料,5月14日股价下跌3.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635745685","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635745685?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:12","pubTimestamp":1778767936,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘,前沿生物报收于22.78元,较前一交易日下跌3.96%,最新总市值为85.33亿元。该股当日开盘23.64元,最高24.1元,最低22.76元,成交额达4.1亿元,换手率为4.71%。近日,前沿生物药业(南京)股份有限公司披露《2025年年度股东会会议资料》。公司2025年度亏损26,805.30万元,不进行利润分配。董事会共召开8次会议,持续推进公司治理体系建设。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400042814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634640998","title":"5月11日前沿生物涨8.40%,易方达医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634640998","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2634640998?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:30","pubTimestamp":1778488238,"startTime":"0","endTime":"0","summary":"证券之星消息,5月11日前沿生物涨8.40%,收盘报24.4元,换手率8.43%,成交量31.58万手,成交额7.44亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共10家,其中持有数量最多的公募基金为易方达基金的易方达医疗保健行业混合A。易方达医疗保健行业混合A目前规模为32.51亿元,最新净值3.907,较上一交易日下跌2.01%,近一年上涨17.05%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789542469533,"stockEarnings":[{"period":"1week","weight":-0.0864},{"period":"1month","weight":-0.2927},{"period":"3month","weight":-0.1294},{"period":"6month","weight":-0.1843},{"period":"1year","weight":0.013},{"period":"ytd","weight":-0.1391}],"compareEarnings":[{"period":"1week","weight":-0.0194},{"period":"1month","weight":-0.016},{"period":"3month","weight":-0.0593},{"period":"6month","weight":-0.0355},{"period":"1year","weight":0.001},{"period":"ytd","weight":-0.0263}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"前沿生物药业(南京)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20043人(较上一季度增加23.58%)","perCapita":"18688股","listingDate":"2020-10-28","address":"江苏省南京市江宁区至道路8号","registeredCapital":"37457万元","survey":" 前沿生物药业(南京)股份有限公司的主营业务是抗病毒和肌肉骨骼疼痛治疗药物的研发、生产和销售。公司的主要产品是艾可宁。公司斩获多项政府及行业荣誉,获评国家专精特新小巨人企业、江苏省企业技术中心、江苏瞪羚企业、中国制药工业TOP101;同时入选南京生物医药产业创新投资促进会第一届会员成就榜,取得海外BD开拓成就榜、社会责任与公益贡献成就榜、协会发展特别贡献榜多项荣誉。","listedPrice":20.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"前沿生物-U(688221)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供前沿生物-U(688221)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"前沿生物-U,688221,前沿生物-U股票,前沿生物-U股票老虎,前沿生物-U股票老虎国际,前沿生物-U行情,前沿生物-U股票行情,前沿生物-U股价,前沿生物-U股市,前沿生物-U股票价格,前沿生物-U股票交易,前沿生物-U股票购买,前沿生物-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"前沿生物-U(688221)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供前沿生物-U(688221)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}